HeyJaredMarie Bergado
- Indexed articles, last 90 days
- 4
- Latest publication
- Sep 5, 2026
- Outlet visibility, for Whatech
- Top 5M sites
- Earliest in this view
- Sep 4, 2026
Latest articles
CMS (867.HK/8A8.SG): Innovative Drug Lumirix(R) Approved in China for Additional Indication of Atopic Dermatitis (AD) (opens the original)
Read excerpt
SHENZHEN, CHINA - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited) received the approval from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (Lumirix®) for th
Fashion Hong Kong delivers a sensory surge of urban energy (opens the original)
Read excerpt
- Four local labels explore 'Hong Kong Dopamine' to translate the city's unique pulse into a fashion language HONG KONG, Sep 4, 2026 - (ACN Newswire) - Asia's annual fashion extravaganza CENTRESTAGE kicked off on 2 September, followed by the highly anticipated Fashion Hong Kong Runway Show last night. The spectacular show featured the meticulously crafted Spring/Summer 2027 collections of four prominent local fashion brands: 112 mountainyam, ANGUS TSUI, ARTY:ACTIVE, and Z I D I. (front row from
CENTRESTAGE ELITES presents KIT WAN STUDIOS, A star-studded fashion extravaganza features sci-fi aesthetics with over 30 new creations (opens the original)
Read excerpt
HONG KONG, Sept 3, 2026 - (ACN Newswire) - Organised by the Hong Kong Trade Development Council (HKTDC) and sponsored by the Cultural and Creative Industries Development Agency (CCIDA) of the Hong Kong Special Administrative Region (HKSAR) Government, CENTRESTAGE, Asia’s annual premier fashion event and a flagship programme of the third edition of Hong Kong Fashion Fest, takes place at the Hong Kong Convention and Exhibition Centre (HKCEC) from 2 to 5 September 2026. As a dazzling focal point of
Everest Medicines Strengthens Its Cardiovascular Portfolio with CARDAMYST(R) Approved for the Conversion of Acute Symptomatic Episodes of PSVT to Sinus Rhythm in Adults in China (opens the original)
Read excerpt
HONG KONG, Sept 3, 2026 - (ACN Newswire) - Everest Medicines today announced that China’s National Medical Products Administration (NMPA) has approved CARDAMYST(R) (etripamil) for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. As Everest's first innovative therapy approved in the cardiovascular field, CARDAMYST further expands the Company‘s cardiovascular portfolio. The approval marks another important milestone in the ex
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5M sites
For Whatech, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.